甲状腺相关眼病眼表损伤特征分析

马骋宇 ,  马佳 ,  解颖 ,  李洋 ,  谢心远 ,  董志军

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (9) : 847 -850.

PDF (378KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (9) : 847 -850. DOI: 10.12007/j.issn.0258‐4646.2026.09.014
论著

甲状腺相关眼病眼表损伤特征分析

作者信息 +

Characteristics of ocular surface damage in thyroid-associated ophthalmopathy

Author information +
文章历史 +
PDF (386K)

摘要

目的 观察并分析甲状腺相关眼病 (TAO) 患者眼表损伤的特征。方法 选取2023年11月至2024年12月间在我院确诊为TAO的患者33例 (65眼),根据临床活动性评分 (CAS) 将其分为活动期TAO组 (17例,33眼) 和静止期TAO组 (16例,32眼),选取同期健康志愿者15例 (30眼) 作为对照组。比较3组外眼、眼表及睑板腺指标的差异,并探讨其与眼表暴露因素的关系。结果 与对照组比较,活动期TAO组、静止期TAO组的眼球突出度、睑裂高度、眼表疾病指数评分 (OSDI)、角膜荧光素染色 (CFS)评分、上睑板腺缺失率、下睑板腺缺失率、睑脂质量评分、睑板腺表达能力评分均明显升高 (均P < 0.05),首次泪膜破裂时间 (NITBUTf)、平均泪膜破裂时间 (NITBUTav)、下泪河高度 (LTMH)、泪液分泌量 (SⅠT) 均明显降低 (均P < 0.05)。与静止期TAO组比较,活动期TAO组的眼球突出度、睑裂高度、OSDI、CFS评分、上睑板腺缺失率、下睑板腺缺失率、睑脂质量评分、睑板腺表达能力评分均明显升高 (均P < 0.05),NITBUTf、NITBUTav、LTMH、SⅠT均明显降低 (均P < 0.05)。TAO患者的OSDI、CFS、上睑板腺缺失率、下睑板腺缺失率、睑脂质量评分及睑板腺表达能力评分与眼球突出度、睑裂高度呈正相关 (均P < 0.05),NITBUTf、NITBUTav、LTMH、SⅠT与眼球突出度、睑裂高度呈负相关 (均P < 0.05)。结论 TAO患者存在眼表损伤,主要表现为眼表不适症状加重、泪膜稳定性下降、角膜上皮损伤、泪液分泌不足、LTMH降低、睑板腺缺失及功能障碍,且活动期TAO患者的眼表损伤程度较静止期更重,而眼表暴露增加是TAO眼表损伤的重要原因。

Abstract

Objective To observe and analyze the characteristics of ocular surface damage in thyroid-associated ophthalmopathy (TAO). Methods Thirty-three patients with TAO (65 eyes) from November 2023 to December 2024 were analyzed. The patients were divided into an active TAO group (17 patients,33 eyes) and an non-active TAO group (16 patients,32 eyes) based on clinical activity score (CAS). Fifteen healthy volunteers (30 eyes) were selected as controls. External eye,ocular surface,and meibomian gland examinations were compared among the three groups. Results Compared to the control group,both TAO groups showed significantly increased exophthalmos,palpebral fissure height,OSDI,CFS,meibomian gland dropout rates,meibum quality score,and expressibility score (all P < 0.05),whereas NITBUTf,NITBUTav,LTMH,and SⅠT decreased significantly (all P < 0.05). The active TAO group showed more severe changes than the non-active TAO group (all P < 0.05). Correlation analysis showed that the OSDI,CFS,and meibomian parameters were positively correlated with exophthalmos and palpebral fissure height (all P < 0.05),whereas NITBUTf,NITBUTav,LTMH,and SⅠT were negatively correlated (all P < 0.05). Conclusion Patients with TAO exhibited ocular surface damage,including aggravated subjective symptoms,decreased tear film stability,corneal epithelial damage,insufficient tear secretion,reduced lower tear meniscus height,and meibomian gland loss or dysfunction. Severity was more pronounced in patients with active TAO. Increased ocular surface exposure significantly contributes to ocular surface damage observed in TAO.

关键词

甲状腺相关眼病 / 眼表损伤 / 泪膜 / 睑板腺 / 眼表暴露 / 眼表面干涉仪

Key words

thyroid-associated ophthalmopathy / ocular surface damage / tear film / meibomian gland / ocular surface exposure / ocular surface interferometer

引用本文

引用格式 ▾
马骋宇,马佳,解颖,李洋,谢心远,董志军. 甲状腺相关眼病眼表损伤特征分析[J]. 中国医科大学学报, 2026, 55(9): 847-850 DOI:10.12007/j.issn.0258‐4646.2026.09.014

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

BURCH HB,PERROS P,BEDNARCZUK T,et al. Management of thyroid eye disease:a consensus statement by the American Thyroid Association and the European Thyroid Association [J]. Thyroid,2022,32 (12):1439-1470. DOI:10.1089/thy.2022.0251.

[2]

NESET MT,NILSEN RM,LØVÅS K,et al. Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease [J]. Acta Ophthalmol,2026,104 (1):e28-e38. DOI:10.1111/aos.17556.

[3]

中华医学会眼科学分会眼整形眼眶病学组,中华医学会内分泌学分会甲状腺学组,范先群,等. 中国甲状腺相关眼病诊断和治疗指南 (2022年) [J]. 中华眼科杂志,2022,58 (9):646-668. DOI:10.3760/cma.j.cn112142-20220421-00201.

[4]

LIAO X,LAI KKH,ALI ABDULLA ALJUFAIRI FM,et al. Ocular surface changes in treatment-naive thyroid eye disease [J]. J Clin Med,2023,12 (9):3066. DOI:10.3390/jcm12093066.

[5]

NIVEAN PD,SHETTY R,SETHU S,et al. Role of biomarkers in south Indian thyroid eye disease study (SITED) [J]. Orbit,2025,44 (5):489-497. DOI:10.1080/01676830.2025.2453536.

[6]

KIYAT P,SEMIZ G. Selenium:could it be the game-changer for ocular surface and anterior chamber in Graves’ disease? [J]. Beyoglu Eye J,2025,10 (3):181-187. DOI:10.14744/bej.2025.38700.

[7]

MAGLIONICO MN,LANZOLLA G,FIGUS M,et al. Ocular surface disease index in Graves’ orbitopathy:a cross-sectional study [J]. Front Endocrinol,2024,15:1428185. DOI:10.3389/fendo.2024.1428185.

[8]

RANA K,CALTABIANO C,BEECHER M,et al. Lacrimal gland enlargement in thyroid eye disease [J]. Int Ophthalmol,2024,44 (1):431. DOI:10.1007/s10792-024-03352-x.

[9]

CHENG SN,YU YQ,CHEN J,et al. In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves’ orbitopathy [J]. BMC Ophthalmol,2021,21 (1):261. DOI:10.1186/s12886-021-02024-z.

[10]

YOU Y,CHEN J,CHEN H,et al. Investigation of conjunctival goblet cell and tear MUC5AC protein in patients with Graves’ ophthalmopathy [J]. Trans Vis Sci Tech,2023,12 (10):19. DOI:10.1167/tvst.12.10.19.

[11]

SATITPITAKUL V,RATTANAPHONG T,PRUKSAKORN V. Meibomian glands dropout in patients with inactive thyroid related orbitopathy [J]. PLoS One,2021,16 (4):e0250617. DOI:10.1371/journal.pone.0250617.

[12]

LAI KKH,LIAO XL,ALI ABDULLA ALJUFAIRI FM,et al. Ocular surface and meibomian gland evaluation in euthyroid Graves’ ophthalmopathy [J]. Int Ophthalmol,2024,44 (1):124. DOI:10.1007/s10792-024-02919-y.

基金资助

承德市科技计划(202303A049)

AI Summary AI Mindmap
PDF (378KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉